Reaction Details Report a problem with these data
Target
Mitogen-activated protein kinase 9
Ligand
BDBM50333992
Substrate
n/a
Meas. Tech.
ChEMBL_701206 (CHEMBL1648826)
IC50
220±n/a nM
Citation
Probst, GD; Bowers, S; Sealy, JM; Truong, AP; Hom, RK; Galemmo, RA; Konradi, AW; Sham, HL; Quincy, DA; Pan, H; Yao, N; Lin, M; Tóth, G; Artis, DR; Zmolek, W; Wong, K; Qin, A; Lorentzen, C; Nakamura, DF; Quinn, KP; Sauer, JM; Powell, K; Ruslim, L; Wright, S; Chereau, D; Ren, Z; Anderson, JP; Bard, F; Yednock, TA; Griswold-Prenner, I Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration. Bioorg Med Chem Lett 21:315-9 (2010) [PubMed] Article
More Info.:
Target
Name:
Mitogen-activated protein kinase 9
Synonyms:
JNK-55 | JNK2 | JNK2/JNK3 | MAPK9 | MK09_HUMAN | Mitogen-Activated Protein Kinase 9 (JNK2) | Mitogen-activated protein kinase 8/9 | PRKM9 | SAPK1A | Stress-activated protein kinase JNK2 | c-Jun N-terminal kinase 2 | c-Jun N-terminal kinase 2 (JNK2)
Type:
Enzyme
Mol. Mass.:
48131.49
Organism:
Homo sapiens (Human)
Description:
JNK-2 was purchased from Upstate Cell Signaling Solutions (formerly Upstate Biotechnology).
Residue:
424
Sequence:
MSDSKCDSQFYSVQVADSTFTVLKRYQQLKPIGSGAQGIVCAAFDTVLGINVAVKKLSRPFQNQTHAKRAYRELVLLKCVNHKNIISLLNVFTPQKTLEEFQDVYLVMELMDANLCQVIHMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTACTNFMMTPYVVTRYYRAPEVILGMGYKENVDIWSVGCIMGELVKGCVIFQGTDHIDQWNKVIEQLGTPSAEFMKKLQPTVRNYVENRPKYPGIKFEELFPDWIFPSESERDKIKTSQARDLLSKMLVIDPDKRISVDEALRHPYITVWYDPAEAEAPPPQIYDAQLEEREHAIEEWKELIYKEVMDWEERSKNGVVKDQPSDAAVSSNATPSQSSSINDISSMSTEQTLASDTDSSLDASTGPLEGCR